2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
3137
Neoplasms
2474
Carcinoma, Non-Small-Cell Lung
1883
Prostatic Neoplasms
1641
Colorectal Neoplasms
1432
Lung Neoplasms
1308
Multiple Myeloma
937
Neoplasm Metastasis
926
Leukemia, Myeloid, Acute
885
Pancreatic Neoplasms
860
Ovarian Neoplasms
814
Melanoma
791
Carcinoma, Hepatocellular
743
Stomach Neoplasms
647
Recurrence
640
Brain Neoplasms
640
Squamous Cell Carcinoma of Head and Neck
638
Head and Neck Neoplasms
609
Glioblastoma
573
Uterine Cervical Neoplasms
549
Lymphoma
549
Triple Negative Breast Neoplasms
514
Precursor Cell Lymphoblastic Leukemia-Lymphoma
511
Carcinoma, Renal Cell
504
Endometrial Neoplasms
467
Hematologic Neoplasms
464
Urinary Bladder Neoplasms
462
Colonic Neoplasms
447
Lymphoma, Non-Hodgkin
437
Sarcoma
436
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
1 year
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled